Medical experts discuss strategies to connect with patients to alleviate concerns potentially associated with converting heart failure therapies.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. The panel discusses strategies for converting stable heart failure patients from angiotensin-converting enzyme (ACE) inhibitors to angiotensin receptor-neprilysin inhibitor (ARNI) therapy. Albert emphasizes shared decision-making, explaining the benefits of switching, trying the new therapy, and reassessing how the patient feels. Once aware of improvements, patients are motivated to continue. Albert notes explaining therapeutic mechanisms helps, as ARNIs can actually reduce heart size versus just preventing enlargement with ACE inhibitors. Another of the 4 pillars of heart failure (HF) therapy, sodium-glucose cotransporter-2 (SGLT2) inhibitors, emerged unexpectedly from diabetes trials, reducing cardiovascular deaths across ejection fraction ranges. The ability to use SGLT2 inhibitors across HF spectrums makes adoption easier. For primary prevention, high-risk diabetes patients should receive SGLT2 inhibitors. In summary, SGLT2 inhibitors have rapidly become a core HF therapy thanks to unexpected cardiovascular benefits seen in diabetes trials. Their broad applicability creates substantial opportunities to improve outcomes across HF populations.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
2 Commerce Drive
Cranbury, NJ 08512